A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS.
DrugDrug NameDrug Indication
DB00009AlteplaseFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
DB00013UrokinaseUrokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
DB00015ReteplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00029AnistreplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00031TenecteplaseFor treatment of myocardial infarction and lysis of intracoronary emboli
DB00036Coagulation factor VIIa Recombinant HumanFor treatment of hemorrhagic complications in hemophilia A and B
DB00042Botulinum Toxin Type BFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
DB00048Collagenase clostridium histolyticumUsed to promote debridement of necrotic tissue in the treatment of severe burns and dermal ulcers including decubitus ulcers.
DB00083Botulinum toxin type AFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
DB00086StreptokinaseFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DB04919AlfimepraseAlfimeprase is being evaluated as a potential treatment for acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB05099AncrodAncrod is indicated for the treatment of deep vein thrombosis (DVT), central retinal branch vein thrombosis, pripaism, pulmonary hypertension of embolic origin, embolism after insertion of prosthetic cardiac valves, rethrombosis after thrombolytic therapy, rethrombosis after vascular surgery, and prevention of DVT after repair of a fractured neck of a femur.
DB05254FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
DB05584PraconaseInvestigated for use/treatment in spinal cord injuries.
DB06245LanoteplaseInvestigated for use/treatment in myocardial infarction.
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB06752ChymopapainChymopapain is indicated for the development of chemonucleolysis which is used for the digestion of the nucleus pulposus in patients with disc herniation confirmed by myelography.[A32687] A disc herniation occurs when the outer portion of the spinal disc breaks down and the inner portion (nucleus pulposus) leaks out pressing surrounding nerves and leading to irradiating pain.[L2496] The chemonucleolysis is a non-surgical treatment that involves the injection of an enzyme to dissolve the nucleus pulposus.[L2482]
DB08839SerotoninNot Available
DB08888OcriplasminOcriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
DB09005BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
DB09375ChymotrypsinNo therapeutic indications.
DB11193PapainNo FDA-approved therapeutic indications.
DB11237TrypsinNot Available
DB11300ThrombinBovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. Additionally, topical bovine thrombin can also be used in combination with an absorbable gelatin sponge, USP [FDA Label].
DB11668Rusalatide acetateNot Available
DB11690VonapanitaseNot Available
DB12249Stem bromelainThe primary medical purpose for which stem bromelain (SB) is currently indicated for is the removal of eschar in adults with deep partial- and full-thickness thermal burns [FDA Label]. Besides this official indication, however, it is also believed that SB may be used as a treatment for several other purposes as well, including cardiovascular health, osteoarthritis, autoimmunity, blood clotting, diarrhea, cancer, surgery, and debridement - although the specific mechanisms of action for these indications remain to be elucidated [A27198].
DB12409Vatreptacog alfaNot Available
DB12726MonteplaseNot Available
DB13197KallidinogenaseNot Available
DB13198PepsinUsed as a pancreatic enzyme replacement in pancreatic insufficiency [L2357]. It is intended to mimic naturally produced human pepsin [L2360]. Pepsin powder is prepared from the gastric mucosa of pigs, cattle or sheep [L2367]. In the laboratory, it is primarily used for the unspecific hydrolysis of proteins and peptides in acidic media. In addition, it provides limited hydrolysis of native immunoglobulins, yielding biologically active fragments [L2353]. In certain supplements, pepsin may be combined with betaine and HCl (hydrochloric acid) to aid in digestion in various gastrointestinal conditions [L2360], [L2352].
DB13199BrinaseNot Available
DB13281BromelainsNot Available
DB13646SaruplaseNot Available
DB14562Andexanet alfaAndexanet alfa is indicated for patients treated with [rivaroxaban] and [apixaban], when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding [L3725]. Andexxa has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any Factor Xa inhibitors other than apixaban and rivaroxaban [L3725].
DB09379SutilainSutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.[T169]
DB15329NattokinaseNot Available
DB11572Thrombin alfaIndicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age [FDA Label]. Additionally, thrombin alfa can be used in conjunction with an absorbable gelatin sponge, USP [FDA Label].
DrugDrug NameTargetType
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factortarget
DB00036Coagulation factor VIIa Recombinant HumanSerine protease hepsintarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
DB00036Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 1target
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 2target
DB00042Botulinum Toxin Type BSynaptotagmin-2target
DB00048Collagenase clostridium histolyticumCollagen alpha-1(I) chaintarget
DB00048Collagenase clostridium histolyticumCollagen alpha-1(II) chaintarget
DB00048Collagenase clostridium histolyticumCollagen alpha-1(III) chaintarget
DB00048Collagenase clostridium histolyticumCollagen alpha-2(I) chaintarget
DB00083Botulinum toxin type ASynaptosomal-associated protein 25target
DB00083Botulinum toxin type ARho-related GTP-binding protein RhoBtarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB04919AlfimepraseFibrinogen alpha chaintarget
DB04919AlfimepraseFibrinogen beta chaintarget
DB05099AncrodFibrinogen alpha chaintarget
DB05254FibrinolysinPlasminogen activator inhibitor 1target
DB05254FibrinolysinUrokinase-type plasminogen activatortarget
DB06245LanoteplaseUrokinase plasminogen activator surface receptortarget
DB06245LanoteplaseFibrinogen alpha chaintarget
DB06245LanoteplaseLaminin subunit alpha-5target
DB06245LanoteplaseCoagulation factor Xtarget
DB06245LanoteplasePlasminogen activator inhibitor 2target
DB06245LanoteplaseKeratin, type II cytoskeletal 8target
DB06245LanoteplaseAnnexin A2target
DB06245LanoteplaseLaminin subunit beta-1target
DB06245LanoteplaseLaminin subunit gamma-1target
DB06245LanoteplaseLaminin subunit alpha-1target
DB06245LanoteplaseProlow-density lipoprotein receptor-related protein 1target
DB06245LanoteplaseLaminin subunit alpha-3target
DB06752ChymopapainBone marrow proteoglycantarget
DB08839SerotoninSolute carrier family 22 member 2transporter
DB08839SerotoninSodium-dependent serotonin transportertarget
DB08839Serotonin5-hydroxytryptamine receptor 2Atarget
DB08839Serotonin5-hydroxytryptamine receptor 3Atarget
DB08839Serotonin5-hydroxytryptamine receptor 3Btarget
DB08839SerotoninSynaptic vesicular amine transportertarget
DB11193PapainToll-like receptor 4target
DB11300ThrombinProteinase-activated receptor 1target
DB11300ThrombinProteinase-activated receptor 4target
DB11300ThrombinCoagulation factor XItarget
DB11300ThrombinCoagulation factor XIII A chaintarget
DB11300ThrombinCoagulation factor XIII B chaintarget
DB11300ThrombinFibrinogen alpha chaintarget
DB11300ThrombinFibrinogen beta chaintarget
DB11300ThrombinFibrinogen gamma chaintarget
DB11300ThrombinCoagulation factor Vtarget
DB11300ThrombinCoagulation factor VIIItarget
DB14562Andexanet alfaTissue factor pathway inhibitortarget
DB09379SutilainNecrotic Tissuetarget
DB11572Thrombin alfaCoagulation factor XItarget
DB11572Thrombin alfaCoagulation factor VIIItarget
DB11572Thrombin alfaCoagulation factor Vtarget
DB11572Thrombin alfaCoagulation factor XIII A chaintarget
DB11572Thrombin alfaCoagulation factor XIII B chaintarget
DB11572Thrombin alfaFibrinogen alpha chaintarget
DB11572Thrombin alfaFibrinogen beta chaintarget
DB11572Thrombin alfaFibrinogen gamma chaintarget